Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharma takes over MM-398 European, Asian rights
Originally developed by Hermes BioSciences, MM-398, was acquired by Merrimack in 2009. The tie up allows Merrimack to develop and commercialize MM-398 in all territories of the world
Originally developed by Hermes BioSciences, MM-398, was acquired by Merrimack in 2009. The tie up allows Merrimack to develop and commercialize MM-398 in all territories of the world
The multi-target drug discovery alliance was originally signed in 2004 for the co-identification and co-development of preclinical development candidates targeting various disease areas including CNS, inflammation, cardiometabolic and
NUVIGIL is indicated for the improvement of wakefulness in patients with excessive sleepiness associated with shift work disorder (SWD), treated obstructive sleep apnea (OSA), or narcolepsy. The six-week,
The orphan drug status provides the company for marketing MCD-386CR as a treatment for PSP for seven years. MCD-386 is a selective agonist (activator) for M1-type acetylcholine muscarinic
Revenue for the first quarter of 2011 was $14.7m, consisting of partial recognition of the non-refundable up-front and development milestone payments to date from the company’s corporate partners
Tullman was the co-founder, president and CEO of Ception Therapeutics, which was acquired by Cephalon, in April 2010, and currently serves as chairman of Vicept Therapeutics. Before Ception,
The company has reported a net loss of $6.65m, or $0.07 loss per diluted share, compared to net loss of $15.95m or $0.17 loss per diluted share, for
The company has reported a net income of $431,000, or $0.01 per diluted share, compared to net income of $199.81m or $0.29 loss per diluted share, for the
The test is said to be in development for the European and US in vitro diagnostic (IVD) market. Dynabeads MyOne SILANE are monosized, magnetic beads that bind to
Selvita develops medicines for central nervous system, oncology and autoimmune disorders as well as provision of non-clinical research services. Proceeds from the financing will be used primarily for